EP2427054A4 - Feste formulierungen aus prostacyclin-analogen - Google Patents

Feste formulierungen aus prostacyclin-analogen

Info

Publication number
EP2427054A4
EP2427054A4 EP10772819.8A EP10772819A EP2427054A4 EP 2427054 A4 EP2427054 A4 EP 2427054A4 EP 10772819 A EP10772819 A EP 10772819A EP 2427054 A4 EP2427054 A4 EP 2427054A4
Authority
EP
European Patent Office
Prior art keywords
solid formulations
prostacyclin analogs
prostacyclin
analogs
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10772819.8A
Other languages
English (en)
French (fr)
Other versions
EP2427054A1 (de
Inventor
Kenneth Robert Phares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43050464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2427054(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of EP2427054A1 publication Critical patent/EP2427054A1/de
Publication of EP2427054A4 publication Critical patent/EP2427054A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP10772819.8A 2009-05-07 2010-05-06 Feste formulierungen aus prostacyclin-analogen Withdrawn EP2427054A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17626809P 2009-05-07 2009-05-07
PCT/US2010/033852 WO2010129757A1 (en) 2009-05-07 2010-05-06 Solid formulations of prostacyclin analogs

Publications (2)

Publication Number Publication Date
EP2427054A1 EP2427054A1 (de) 2012-03-14
EP2427054A4 true EP2427054A4 (de) 2014-01-15

Family

ID=43050464

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10772819.8A Withdrawn EP2427054A4 (de) 2009-05-07 2010-05-06 Feste formulierungen aus prostacyclin-analogen

Country Status (7)

Country Link
US (1) US8349892B2 (de)
EP (1) EP2427054A4 (de)
JP (1) JP5649645B2 (de)
KR (1) KR101544246B1 (de)
CN (1) CN102421288B (de)
CA (1) CA2760499C (de)
WO (1) WO2010129757A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102697790A (zh) 2003-05-22 2012-10-03 联合治疗公司 化合物和释放前列环素类似物的方法
CN101287457B (zh) * 2004-04-12 2011-11-16 联合治疗公司 Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
WO2007134292A2 (en) 2006-05-15 2007-11-22 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
KR101898407B1 (ko) 2007-12-17 2018-09-12 유나이티드 세러퓨틱스 코오포레이션 레모둘린®의 활성 성분인 트레프로스티닐의 개선된 제조 방법
ES2790859T3 (es) 2010-03-15 2020-10-29 United Therapeutics Corp Tratamiento para hipertensión pulmonar
CA2777070C (en) 2010-06-03 2019-11-05 United Therapeutics Corporation Treprostinil production
WO2011159693A2 (en) * 2010-06-15 2011-12-22 United Therapeutics Corporation Oral treatment of digital ischemic lesions
EP2681204B1 (de) 2011-03-02 2016-04-27 United Therapeutics Corporation Synthese von zwischenprodukten zur treprostinilherstellung
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2927844T3 (es) 2013-01-11 2022-11-11 Corsair Pharma Inc Profármacos de treprostinil
KR102347340B1 (ko) 2013-03-14 2022-01-06 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐의 고체 형태
JP2016516693A (ja) 2013-03-15 2016-06-09 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの塩
KR102238501B1 (ko) 2013-03-25 2021-04-08 유나이티드 세러퓨틱스 코오포레이션 링커 티올 및 peg화된 형태를 갖는 프로스타시클린 화합물의 제조 방법
CN108947843A (zh) 2013-10-25 2018-12-07 英斯梅德股份有限公司 前列环素化合物、其组合物及使用方法
JP2017517550A (ja) 2014-06-13 2017-06-29 ユナイテッド セラピューティクス コーポレイション トレプロスチニル製剤
US9593061B2 (en) 2014-10-20 2017-03-14 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
JP6866043B2 (ja) 2014-11-18 2021-04-28 インスメッド インコーポレイテッド トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
CA3038276A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
WO2020223237A1 (en) 2019-04-29 2020-11-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
AU2021255621A1 (en) 2020-04-17 2022-10-20 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
JP2023529828A (ja) 2020-06-09 2023-07-12 ユナイテッド セラピューティクス コーポレイション トレプロスチニルのフマリルジケトピペリジンプロドラッグ
WO2022132655A1 (en) 2020-12-14 2022-06-23 United Therapeutics Corporation Methods of treating disease with treprostinil prodrugs
CN117479946A (zh) 2021-03-03 2024-01-30 联合治疗公司 含曲前列环素及其前药并还包含(e)-3,6-双[4-(n-羰基-2-丙烯基)酰胺丁基]-2,5-二酮哌嗪(fdkp)的干粉组合物
WO2023154705A1 (en) 2022-02-08 2023-08-17 United Therapeutics Corporation Treprostinil iloprost combination therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249167A1 (en) * 2003-05-22 2008-10-09 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
GB9011588D0 (en) 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6054486A (en) 1997-11-14 2000-04-25 United Technology Corporation Use of 9-Deoxy-2',9-α-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen e)-13,14-dihydro-prostaglandin f1 to treat peripheral vascular disease
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6700025B2 (en) 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
EP1471049A4 (de) * 2002-01-30 2006-08-16 Kissei Pharmaceutical Neuer ligand für den thyroidhormonrezeptor, diesen enthaltende medizinische zusammensetzungen und deren verwendung
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20050101608A1 (en) 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
CN1917883B (zh) 2003-12-16 2011-05-11 联合治疗公司 曲前列环素在制备改善肾功能的药物中的用途
CN1917866B (zh) 2003-12-16 2010-12-15 联合治疗公司 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途
CN101287457B (zh) 2004-04-12 2011-11-16 联合治疗公司 Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
AP2007004067A0 (en) * 2005-02-22 2007-08-31 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
US20060222792A1 (en) 2006-04-21 2006-10-05 Chemagis Ltd. Temozolomide storage system
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
WO2007134292A2 (en) 2006-05-15 2007-11-22 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
US20090281129A1 (en) 2006-05-15 2009-11-12 Senex Biotechnology, Inc. Cdki pathway inhibitors and uses thereof
MX2009006692A (es) 2006-12-21 2009-06-30 Concert Pharmaceuticals Inc Derivados de prostaciclina.
WO2008098196A1 (en) 2007-02-09 2008-08-14 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
EP2079445B1 (de) * 2007-02-20 2015-11-04 Aptalis Pharma Limited Stabile verdauungsenzymzusammensetzungen
KR101898407B1 (ko) 2007-12-17 2018-09-12 유나이티드 세러퓨틱스 코오포레이션 레모둘린®의 활성 성분인 트레프로스티닐의 개선된 제조 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249167A1 (en) * 2003-05-22 2008-10-09 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PHARES KENNETH R ET AL: "Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents.", vol. 60, no. 9, 1 May 2003 (2003-05-01), pages 9PP, XP002716292, Retrieved from the Internet <URL:http://www.medscape.com/viewarticle/453037> [retrieved on 20131113] *
See also references of WO2010129757A1 *

Also Published As

Publication number Publication date
KR20120017058A (ko) 2012-02-27
JP5649645B2 (ja) 2015-01-07
CA2760499A1 (en) 2010-11-11
WO2010129757A1 (en) 2010-11-11
JP2012526140A (ja) 2012-10-25
EP2427054A1 (de) 2012-03-14
CN102421288B (zh) 2015-04-22
US20100282622A1 (en) 2010-11-11
CN102421288A (zh) 2012-04-18
US8349892B2 (en) 2013-01-08
KR101544246B1 (ko) 2015-08-12
CA2760499C (en) 2015-11-03

Similar Documents

Publication Publication Date Title
EP2427054A4 (de) Feste formulierungen aus prostacyclin-analogen
HK1254977A1 (zh) 索非布韋(sofosbuvir)的結晶形式
IL246900A0 (en) Polymorphs of Dronir
HK1198358A1 (en) Sustained release composition of prostacyclin
ZA201204459B (en) Formulations of antibody
HK1165333A1 (en) Oxyntomodulin analogs
EP2510089A4 (de) Synthese von prazolverbindungen
EP2504020A4 (de) Daptomycin-formulierungen
EP2477628A4 (de) Herstellung kristalliner formen von dihydropyrazolopyrimidinon
EP2454227A4 (de) Prostanoid-synthese
EP2462115A4 (de) Enzymatische transaminierung von cyclopamin-analogen
EP2515654A4 (de) Neue ergolinanaloga
EP2513116A4 (de) Darunavir-polymorphe
PL2442648T3 (pl) Preparaty neonikotynoidów niezawierające nmp
EP2575839A4 (de) Oral verabreichbare formulierungen zur bekämpfung von alterungseffekten
ZA201104894B (en) Solid oral formulations of a pyridopyrimidinone
EP2552423A4 (de) Stabilisierte formulierungen aus cns-verbindungen
EP2552210A4 (de) Formulierungen aus mazindol
PL2407155T3 (pl) Formulacje inekalcytolu
EP2512489A4 (de) Formulierungen aus acadesin
GB0908711D0 (en) Preparation of labelled compounds
GB0922023D0 (en) Preparation of n-monofluoroalkyl compounds
IL209833A0 (en) Solid dosage formulations of telcagepant potassium
SI2504309T1 (sl) Sinteza acetokslacetaldehida
EP2459540A4 (de) Herstellung von fipamezol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/215 20060101ALI20131120BHEP

Ipc: A01N 37/08 20060101AFI20131120BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 37/08 20060101AFI20131205BHEP

Ipc: A61K 31/215 20060101ALI20131205BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20131213

17Q First examination report despatched

Effective date: 20170512

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190205